Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CASI Starts China Arm of Phase II Breast Cancer Trial

publication date: Mar 25, 2015
CASI Pharma, a US biopharma with strong China connections, has begun a China Phase II trial of its lead molecule, ENMD-2076, in triple-negative breast cancer. The trial is a China arm of an on-going Phase II test in the US. The China trial, which is being conducted at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, will assess the safety and efficacy of ENMD-2076 in a Chinese population along with analysis of a bio-marker. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital